Key Takeaways

Ipamorelin acetate is often presented as a gentler way to obtain the benefits associated with growth hormone.
The evidence supports a narrower statement: intravenous ipamorelin can trigger a short growth-hormone pulse, and rodent studies show endocrine, bone, body-weight, and gastrointestinal effects under experimental conditions.
It does not follow that compounded subcutaneous ipamorelin acetate safely improves body composition, sleep, recovery, performance, or longevity in people.

‍

[Gobburu et al., 1999; Johansen et al., 1999; Jiménez-Reina et al., 2002; Beck et al., 2014; FDA, 2026a].

Ipamorelin acetate: an unapproved, investigational acetate-salt form of the synthetic amidated pentapeptide growth-hormone secretagogue ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2), with narrow human intravenous pharmacology data but no established subcutaneous wellness indication, validated long-term safety profile, or FDA-approved drug product.

Overview

The central scientific and compliance problem with ipamorelin acetate is route-and-outcome transfer. Ipamorelin is a real synthetic growth-hormone secretagogue with a defined receptor target and a documented acute growth-hormone response in healthy men receiving intravenous infusions. That narrow pharmacodynamic result is now routinely rewritten in peptide markets as evidence that subcutaneous ipamorelin acetate reduces fat, builds lean mass, improves sleep, accelerates recovery, raises energy, preserves youth, or safely "optimizes" the growth-hormone axis. The public evidence does not support that conversion. [Gobburu et al., 1999; NCATS Inxight Drugs, 2025; AP, 2026; PurePep, 2026]

The same-molecule human program is small and route-specific. In a 1999 dose-escalation study, eight healthy men at each of five intravenous infusion levels showed dose-proportional ipamorelin pharmacokinetics, a terminal half-life near two hours, and one transient growth-hormone pulse that peaked at about 0.67 hours. A later multicenter, randomized Phase 2 trial tested intravenous ipamorelin after bowel resection because ghrelin-receptor agonism was expected to improve postoperative gastrointestinal motility. The trial enrolled 117 patients and found no statistically significant difference in the key or secondary efficacy analyses. Those studies establish acute intravenous pharmacology and an unsuccessful gastrointestinal development hypothesis; they do not establish chronic subcutaneous body-composition, sleep, recovery, or anti-aging efficacy. [Gobburu et al., 1999; Beck et al., 2014]

Regulatory posture is materially cautionary. FDA currently lists ipamorelin acetate in 503B Category 2, the interim-policy category for nominated bulk substances that may present significant safety risks. FDA cites potential immunogenicity from aggregation or peptide-related impurities, added characterization complexity from unnatural amino acids, serious adverse events including death in intravenous gastric-motility use, and a lack of safety information for certain other injectable routes. The prior 503A nomination was withdrawn, but the substance remains active in 503B Category 2. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before marketing. [FDA, 2026a; FDA, 2026b; FDA, 2025]

What it is

Ipamorelin is a synthetic amidated pentapeptide growth-hormone secretagogue. NCATS lists the sequence shorthand Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is alpha-aminoisobutyric acid and D-2-Nal is a non-natural D-2-naphthylalanine residue. The official chemical name is 2-methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide. [NCATS Inxight Drugs, 2025]

"Ipamorelin acetate" usually refers to the peptide supplied with acetate counterions after synthesis and purification. The acetate is not a new efficacy-bearing analogue. It is a salt/formulation label whose exact mass contribution can vary with counterion stoichiometry and hydration. [NCATS Inxight Drugs, 2025; FDA, 2026a]

The most important family distinction is receptor class. Ipamorelin is a ghrelin/growth-hormone-secretagogue receptor agonist, not a growth-hormone-releasing-hormone receptor agonist. Endogenous ghrelin, older growth-hormone-releasing peptides such as GHRP-2 and GHRP-6, GHRH analogs such as sermorelin, CJC-1295, and tesamorelin, and recombinant human growth hormone such as somatropin are related through the GH axis but are not interchangeable molecules. Each has different receptor pharmacology, formulation, clinical evidence, adverse-effect profile, and regulatory status. [Howard et al., 1996; Kojima et al., 1999; Davenport et al., 2005; Moulin et al., 2007]

Material	What it is	Why it cannot be collapsed into "ipamorelin acetate therapy"
Ipamorelin active moiety	Synthetic amidated pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2	This is the pharmacologically active target; its chemical identity does not validate a specific finished vial. [NCATS Inxight Drugs, 2025]
Ipamorelin acetate	Ipamorelin presented as an acetate salt/counterion form	Salt designation does not establish acetate stoichiometry, excipients, purity, sterility, stability, or clinical equivalence. [FDA, 2026a; NCATS Inxight Drugs, 2025]
Endogenous ghrelin	A stomach-derived acylated human peptide and native GHSR ligand	Endogenous physiology does not make synthetic ipamorelin "natural," and ghrelin outcomes do not transfer automatically. [Kojima et al., 1999; Davenport et al., 2005]
GHRP-2, GHRP-6, hexarelin	Other synthetic ghrelin-receptor agonist peptides	Class membership does not establish identical selectivity, hormonal spillover, PK, or safety. [Moulin et al., 2007; Isidro and Cordido, 2006]
Sermorelin, CJC-1295, tesamorelin	GHRH-receptor agonists or analogs	They act through a different receptor and have separate molecule-specific evidence; a CJC blend is a new combination product. [Moulin et al., 2007]
Somatropin / recombinant hGH	Exogenous human growth hormone drug	Direct hormone replacement is not the same intervention as transient secretagogue stimulation. Approved hGH indications do not validate ipamorelin. [FDA, 2026b]
CJC-1295/ipamorelin blend	Two active peptides combined in one marketed "stack" or vial	Market popularity is not controlled synergy evidence, and combined identity/stability cannot be inferred from monotherapy. [AP, 2026; PurePep, 2026]

How it's proposed to work

The most defensible mechanistic anchor is agonism at the growth-hormone secretagogue receptor, usually called GHSR1a or the ghrelin receptor. The receptor was identified in pituitary and hypothalamic tissue as a G-protein-coupled receptor involved in growth-hormone release, and ghrelin was later identified as its endogenous acylated ligand. Ipamorelin was developed as a synthetic peptide agonist of that receptor rather than as a fragment of ghrelin or growth hormone. [Howard et al., 1996; Kojima et al., 1999; Davenport et al., 2005; Raun et al., 1998]

The 1998 foundational paper described ipamorelin as a selective growth-hormone secretagogue in experimental systems, with less ACTH, cortisol, and prolactin stimulation than several older GHRPs under the conditions tested. "Selective" here is comparative pharmacology, not a guarantee of endocrine isolation in every person, route, dose, duration, or combination. The paper does not establish that chronic subcutaneous use leaves cortisol, glucose regulation, appetite, fluid balance, or other systems unaffected. [Raun et al., 1998; FDA, 2026a]

The clearest human pharmacodynamic evidence is acute and intravenous. In healthy male volunteers, a 15-minute ipamorelin infusion produced a single growth-hormone release episode with a peak at approximately 0.67 hours and a decline toward negligible concentrations thereafter; disposition was dose proportional and the terminal half-life was approximately two hours. This supports a transient IV exposure-response relationship. It does not establish the amplitude, frequency, IGF-1 consequences, tachyphylaxis, metabolic effects, or clinical outcomes of repeated subcutaneous ipamorelin acetate. [Gobburu et al., 1999]

A second mechanistic lane involves gastrointestinal motility. Ghrelin-receptor activation can stimulate cholinergic excitatory pathways and gastric contractility, and intravenous ipamorelin accelerated gastric emptying in a rat model of postoperative ileus. That rationale was sufficiently plausible to support human development. The Phase 2 bowel-resection trial, however, did not show a significant improvement in its key or secondary efficacy analyses. [Greenwood-Van Meerveld et al., 2012; Beck et al., 2014]

Common forms in circulation

FDA names "ipamorelin acetate" as the nominated bulk drug substance and places it in 503B Category 2. Those list positions describe compounding-policy status and identified safety concerns; they do not describe an approved dosage form, labeled route, validated concentration, or authorized nationwide clinical use. [FDA, 2026a; FDA, 2025]

Current market discourse centers on lyophilized vials intended for reconstitution, subcutaneous self-injection or clinic-guided injection, and combination products pairing ipamorelin with CJC-1295 or another GHRH-pathway peptide. A live research-market page frames ipamorelin primarily for "fat loss," body composition, muscle, bone, recovery, tissue repair, and energy, while simultaneously labeling it not for human use. These pages document market behavior, not validated use. [AP, 2026; PurePep, 2026]

Names and aliases

Names and variants include ipamorelin, ipamorelin acetate, NNC 26-0161, NNC-26-0161, NNC-260161, "growth-hormone-releasing peptide," "ghrelin mimetic," and "selective GH secretagogue." Common market pairings include CJC-1295/ipamorelin, modified GRF (1-29)/ipamorelin, sermorelin/ipamorelin, tesamorelin/ipamorelin, and multi-peptide "fat-loss," "recovery," or "anti-aging" stacks. Pairing names are market evidence only unless the exact combination, formulation, route, and outcome were studied together. [NCATS Inxight Drugs, 2025; AP, 2026; PurePep, 2026; Business Insider, 2026]

Regulatory status

No FDA-approved ipamorelin or ipamorelin acetate drug product was identified in the reviewed FDA-facing and NCATS sources. NCATS classifies ipamorelin as investigational and links it to completed Phase 2 gastrointestinal-dysmotility development rather than to an approved product. [NCATS Inxight Drugs, 2025; FDA, 2026a]

FDA currently places ipamorelin acetate in 503B Category 2, added September 29, 2023. FDA's stated concerns are unusually specific: potential immunogenicity for certain routes because of aggregation or peptide-related impurities; characterization complexity from unnatural amino acids; serious adverse events including death in intravenous gastric-motility use; and insufficient safety information for certain other injectable routes. [FDA, 2026a]

Ipamorelin is not one of the seven peptides reported for the July 23-24, 2026 PCAC meeting. The listed compounds are BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon. That meeting therefore should not be presented as an imminent ipamorelin review, rescue, or path to approval. [Reuters, 2026]

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before marketing. Clinic availability or a physician consult does not resolve molecule identity, product quality, route-specific safety, or efficacy. [FDA, 2026b; AP, 2026]

Safety

Human therapeutic safety has not been established for the market-dominant subcutaneous use case. The 2014 Phase 2 IV trial reported similar overall treatment-emergent adverse-event incidence between ipamorelin and placebo and described short-term administration as well tolerated, but it was a small, brief inpatient study in a postoperative population and did not establish long-term safety. FDA's 2026 assessment separately states that literature identified serious adverse events including death during IV use for gastric motility. The agency also says it lacks safety information for certain other injectable routes. [Beck et al., 2014; FDA, 2026a]

The main molecule-specific safety unknowns are immunogenicity, aggregate- and impurity-related reactions, route-specific local tolerance, repeat-dose endocrine exposure, and the consequences of chronic GH/IGF-1-axis stimulation. [FDA, 2026a; Isidro and Cordido, 2006; Moulin et al., 2007]

Athlete risk is concrete even when therapeutic claims are not. A UFC athlete received a 12-month anti-doping sanction after an out-of-competition sample tested positive for ipamorelin; the anti-doping authority described it as a prohibited peptide hormone in the peptide-hormones, growth-factors, related-substances, and mimetics category. Tested athletes should not be told that clinic sourcing, injury-recovery intent, or research labeling makes ipamorelin permissible. [MMA Fighting, 2026]

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support	Source
Acute growth-hormone release	In healthy men, IV ipamorelin produced a single transient GH pulse with dose-proportional PK and a peak around 0.67 h.	Does not support "optimizes GH all night," sustained IGF-1 elevation, chronic SC benefit, or clinical improvement.	[Gobburu et al., 1999]
Postoperative GI motility / ileus	IV ipamorelin accelerated gastric emptying in a rat postoperative-ileus model. The human trial showed a numerically shorter median time to first tolerated meal.	The human difference was not statistically significant, and key/secondary analyses were not significant. Do not say it treats ileus or gastroparesis.	[Greenwood-Van Meerveld et al., 2012; Beck et al., 2014]
Muscle gain / lean mass	GH-axis stimulation provides biological plausibility, and some animal work with secretagogues examines anabolic endpoints.	No route-matched human ipamorelin trial establishes increased lean mass, strength, or muscle hypertrophy.	[Raun et al., 1998; PurePep, 2026]
Fat loss / body composition	Market pages connect GH release with lipolysis and label ipamorelin for fat loss.	A transient GH pulse is not a validated fat-loss outcome. No reviewed human SC trial establishes reduced fat mass or weight loss.	[PurePep, 2026; AP, 2026]
Sleep quality	Peptide markets often connect nocturnal GH physiology with deeper sleep.	No same-molecule controlled human trial establishes improved sleep architecture, insomnia treatment, or restorative sleep.	[AP, 2026; Business Insider, 2026]
Recovery / tissue repair	GH and IGF-1 participate in tissue biology, which makes the claim intuitive.	No reviewed human ipamorelin study establishes faster injury healing, postoperative recovery, tendon repair, or reduced soreness.	[AP, 2026; PurePep, 2026]
Bone growth / bone density	Ipamorelin induced longitudinal bone growth in adult female rats in a controlled experiment.	Rat longitudinal growth does not establish prevention or treatment of osteoporosis, fracture reduction, or adult human bone-density benefit.	[Johansen et al., 1999]
Appetite / body-weight change	Chronic ipamorelin exposure increased body-weight gain in young female rats; ghrelin-receptor biology is linked to appetite and energy balance.	It does not support predictable healthy weight gain, selective lean-mass gain, or a fat-loss claim in humans.	[Jiménez-Reina et al., 2002; Davenport et al., 2005]
Athletic performance	GH-axis stimulation creates a performance-enhancement rationale, and ipamorelin has produced an anti-doping sanction.	No evidence establishes safe or effective performance enhancement, and it should not be framed as suitable for tested athletes.	[MMA Fighting, 2026; PurePep, 2026]

Key literature

Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. Identification of the growth hormone secretagogue receptor and its role in GH release.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Relative GH selectivity and early receptor/animal pharmacology.

Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16:1412-1416. Dose-proportional IV PK, ~2 h terminal half-life, and a transient GH pulse in healthy men.

Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. Longitudinal bone-growth effect in an experimental rat model.

Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. IV acceleration of gastric emptying and contractility-related plausibility in rats.

Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-1534. Short-term safety observations and lack of significant efficacy in postoperative ileus.

References

U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Content current June 22, 2026.
National Center for Advancing Translational Sciences. Inxight Drugs: IPAMORELIN, UNII Y9M3S784Z6. Investigational substance record; structure and names updated March 31, 2025.
Associated Press. What's behind the trendy peptide injections being sold by influencers and RFK Jr. allies. 2026.
PurePep. Ipamorelin. 2026.
Business Insider. Reporting on the 2026 peptide-stack and longevity-clinic market, including CJC-1295/ipamorelin-style fat-burning and energy claims. 2026.
MMA Fighting. UFC welterweight Bassil Hafez suspended 1 year after testing positive for banned substance. May 27, 2026.
Reuters. FDA staff question peptides backed by Kennedy ahead of advisory panel review. June 30, 2026; updated July 1, 2026.

Ipamorelin Acetate